Rheumatoid arthritis (RA) is increasingly viewed not as a sudden onset, but as the final phase of a prolonged disease continuum. Years before joint swelling occurs, a distinct ‘at-risk’ state is identifiable. Mounting evidence suggests this pre-clinical phase meets the formal definition of a disease.

Individuals in this at-risk state frequently report a significant clinical burden. Despite lacking visible synovitis, up to 75% of autoantibody-positive patients report debilitating fatigue. Studies using the Health Assessment Questionnaire-Disability Index (HAQ-DI) reveal impairments in function, mood, and quality of life comparable to those seen in established RA or COPD.

The psychological and economic toll is profound. Qualitative studies highlight distress driven by persistent symptoms and uncertainty about progression. Economically, the phase is marked by reduced work productivity and increased healthcare use. A cost-effectiveness analysis for individuals with clinically suspect arthralgia estimated total societal costs between 43,035 EUR and 45,647 EUR over two years, primarily due to impaired work capacity.

Crucially, diagnostic imaging frequently detects subclinical synovitis in these patients, which is linked to functional impairment and progression risk. Interventional trials provide further proof of a meaningful disease state. The TREAT EARLIER trial showed methotrexate improved MRI-detected inflammation and patient-reported outcomes. The APIPPRA and ARIAA trials found that abatacept improved symptoms, imaging scores, and quality of life, while significantly reducing RA progression even after treatment stopped.

Researchers propose a three-stage classification to capture the heterogeneity: Stage 1, asymptomatic autoantibody positivity; Stage 2, symptomatic individuals; and Stage 3, those at highest risk with high-level autoantibodies and subclinical synovitis. As in other conditions like ‘pre-diabetes,’ formalizing a ‘pre-RA’ diagnosis could pave the way for clinical management pathways where none currently exist, despite clear evidence of disease burden and response to therapy.